Generics Bulletin is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Commercial

Strategy Explore this Topic

Set Alert for Strategy

Industry Veteran Haggar To Lead Private Equity-Backed Zentiva From Next Month

Only four months after it was carved out from Sanofi to become an independent company, Prague-based Zentiva has announced fresh leadership in the form of Nick Haggar, the 30-year industry veteran and former president of Medicines of Europe.

Appointments Europe

Pfizer Axes Staff And Five Pre-Clinical Biosimilars To Fund Late-Stage Innovative Programs

With an eye on moving to market its broad pipeline of innovative brands, Pfizer has cut development of five early-stage biosimilar assets, in a decision that will affect 150 staff. The move is not reflective of Pfizer's overall commitment to biosimilars, the US-based company maintains.

Strategy Biosimilars

Amneal Eyes Generic Injectables Deals, While Competition Bites Sooner Than Anticipated

A strengthened cash position has provided Amneal the chance to seek inorganic opportunities to bolster its growing presence in injectables. The US-based, US-centric company is looking to grow its operations, having been surprised in recent weeks by generic competition to its most lucrative generic assets.

Strategy Pricing Debate
See All

Deals Explore this Topic

Set Alert for Deals

Cipla Partners With Bio-Thera For Bevacizumab In Select Emerging Markets

Cipla has formed a licensing agreement with Bio-Thera Solutions for the Chinese firm’s BAT1706 bevacizumab biosimilar, which the Indian company will distribute and sell in select emerging markets.

Biosimilars Deals

Alvotech Advances Partnerships To Take Pipeline Global

By the middle of this year, biosimilars developer Alvotech plans to have strategic alliances in place with a handful of regional partners to commercialize its pipeline of seven biosimilar monoclonal antibodies.
Biosimilars Business Strategies

Mallinckrodt Details Timeline And Financing For Spinning Off Generics Business

Under plans announced last December, Mallinckrodt is to spin off its specialty generics and API business; at the recent Annual J.P. Morgan Healthcare Conference, management painted a timeline to completing the project and provided details on the business’ financing and growth prospects.

Strategy Deals
See All

Manufacturing Explore this Topic

Set Alert for Manufacturing

European Council Brings SPC Manufacturing Waiver A Step Closer

A proposed SPC manufacturing waiver – which would allow generic and biosimilar manufacturing within Europe during the SPC period – has taken a step closer to being realized after the European Council approved a mandate for negotiations with the European Parliament. However, it remains uncertain whether key elements desired by the off-patent industry will fall into place.

Europe Manufacturing

Manufacturing Roundup – 17 January 2019

Dr Reddy’s is hit with a manufacturing setback after getting issued a Form 483 report for its site in Andhra Pradesh, India, while several firms announce site expansions, including in Spain and the US.

Companies Manufacturing

Pfizer To Close Two Former Hospira Sites In India

Pfizer is set to close two of its manufacturing facilities in India this year, after the firm concluded that production at the former Hospira sites “is not viable” due to falling demand.

India Generic Drugs
See All

Sales & Earnings Explore this Topic

Set Alert for Sales & Earnings

Krka firms up its focus on global footprint

Krka is keen to expand its geographic presence beyond its stronghold in Europe, especially by capitalising on the “huge opportunity” in China. But it has no immediate plans to build a major presence in the Americas, according to the Slovenian group’s management board member David Bratoz.

Business Strategies Sales & Earnings

US modafinil charge devastates Sun profit

Sun’s managing director, Dilip Shanghvi, has defended the “underlying health” of the company after a sizeable charge linked to antitrust litigation almost completely wiped out Sun’s pre-tax profit in its financial second quarter, while a sales decline in India limited overall turnover growth.

Sales & Earnings

Nichi-Iko aids Elmed under deal with Eisai

Nichi-Iko has started promoting the value-added portfolio of Eisai’s Elmed in Japan under a strategic alliance struck earlier this year that also includes Nichi-Iko acquiring all shares in Elmed by 1 April 2019. As part of the “phased acquisition” (Generics bulletin, 6 April 2018, page 3), Nichi-Iko said it had by 1 October acquired a third of stocks in Elmed for a total of ¥5.47 billion (US$48.7 million).

Business Strategies Sales & Earnings
See All

People Explore this Topic

Set Alert for People

Industry Veteran Haggar To Lead Private Equity-Backed Zentiva From Next Month

Only four months after it was carved out from Sanofi to become an independent company, Prague-based Zentiva has announced fresh leadership in the form of Nick Haggar, the 30-year industry veteran and former president of Medicines of Europe.

Appointments Europe

Akorn’s Chief Operating Officer Heads For The Exit Days Into Doug Boothe’s Tenure

A month after a court ruled that Fresenius Kabi’s decision to terminate its merger with Akorn was legal and proper, Akorn’s COO has agreed to resign the position, six days after Doug Boothe officially replaced Raj Rai as Akorn’s new president and CEO.

Strategy Leadership

Coherus Confirms Udenyca Launch And Brings In Chief Medical Officer

The California-based biosimilars player has come good on its promise to introduce early in the new year its first biosimilar in the US and the second biosimilar of Amgen’s Neulasta blockbuster; at the same time, biotech veteran Darlene Horton has joined Coherus’ management team.

Launches Biosimilars
See All
UsernamePublicRestriction

Register